Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 7/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 5/20 | 0.33 |
| ▸ | NPY1R | P25929 | 3/20 | 0.33 |
| ▸ | NPY2R | P49146 | 3/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22067692 | 1.00 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL21788282 | 1.00 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL21788261 | 0.91 | FURIN (0.36) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL23900963 | 0.91 | FURIN (0.36) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL23079360 | 0.90 | FURIN (0.39) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL27378298 | 0.90 | FURIN (0.37) | FURINSIRT5NMT2NMT1NPY4R | |
| SCHEMBL24349699 | 0.89 | SIRT5 (0.36) | FURINSIRT5C3AR1NPY4RNPY1R | |
| SCHEMBL20803561 | 0.89 | C3AR1 (0.34) | FURINSIRT5C3AR1SIRT6SIRT1 | |
| SCHEMBL21788077 | 0.89 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL24173258 | 0.89 | C3AR1 (0.34) | FURINSIRT5C3AR1SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953107-B2 | Polypeptide compositions and methods for site-specific targeting of therapeutic agents | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953107-B2 | Polypeptide compositions and methods for site-specific targeting of therapeutic agents | VIP, MICA, ENPEP | FURIN 44/4885SIRT5 4844/4885NMT2 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.